Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials

<div>Primary efficacy outcomes of guselkumab in the treatment of plaque psoriasis versus placebo or adalimumab. PASI: Psoriasis Area and Severity Index; IGA: Investigator’s Global Assessment; DLQI: Dermatology Life Quality Index.</div>

Journal of Immunology Research

fig3

Figure 3

Figure 3: Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials 

Figure 3 | Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials 